The goal of my laboratory is to develop new therapeutic strategies for age-related macular degeneration (AMD).
Advanced AMD (choroidal neovascularization or CNV, and geographic atrophy) is the leading cause of irreversible blindness in the United States and Europe in patients over 55 years of age, affecting more than 1.75 million Americans.
Despite recent advances in the treatment of CNV, clinical outcomes remain suboptimal. Furthermore, there is no effective therapy for atrophic AMD.
